Here are the S-1 registration statements from Longeveron Inc. (LGVN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow LGVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LGVN filings page.
Longeveron Inc. is registering 30,865,385 shares of Class A common stock for resale by existing investors, including shares already issued, shares issuable from preferred stock conversion, and shares underlying placement agent warrants. The company will not receive proceeds from these resales, but could receive up to $1.31 million if all placement agent warrants are exercised in cash.
Longeveron is a clinical-stage biotech focused on its cell therapy candidate laromestrocel (Lomecel-B®) for rare pediatric heart disease (HLHS), Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty. The filing highlights a recent $15.9 million private placement, substantial doubt about the company’s ability to continue as a going concern, and Nasdaq minimum bid-price noncompliance that could lead to a reverse split or potential delisting if not cured.